282 related articles for article (PubMed ID: 34443652)
1. Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone.
Timoshnikov VA; Kichigina LA; Selyutina OY; Polyakov NE; Kontoghiorghes GJ
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443652
[TBL] [Abstract][Full Text] [Related]
2. Redox Interactions of Vitamin C and Iron: Inhibition of the Pro-Oxidant Activity by Deferiprone.
Timoshnikov VA; Kobzeva TV; Polyakov NE; Kontoghiorghes GJ
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486511
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
4. Metal Complexes of Omadine (
Selyutina OY; Timoshnikov VA; Polyakov NE; Kontoghiorghes GJ
Molecules; 2023 May; 28(10):. PubMed ID: 37241949
[TBL] [Abstract][Full Text] [Related]
5. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
Kontoghiorghes GJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
7. Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Hašková P; Applová L; Jansová H; Homola P; Franz KJ; Vávrová K; Roh J; Šimůnek T
Sci Rep; 2022 Jun; 12(1):9765. PubMed ID: 35697900
[TBL] [Abstract][Full Text] [Related]
8. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
Olivieri NF; Sabouhanian A; Gallie BL
PLoS One; 2019; 14(2):e0211942. PubMed ID: 30811439
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
DivakarJose RR; Delhikumar CG; Ram Kumar G
Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Gomber S; Jain P; Sharma S; Narang M
Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine.
Timoshnikov VA; Selyutina OY; Polyakov NE; Didichenko V; Kontoghiorghes GJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163169
[TBL] [Abstract][Full Text] [Related]
13. An ellagic acid isolated from Clerodendrum viscosum leaves ameliorates iron-overload induced hepatotoxicity in Swiss albino mice through inhibition of oxidative stress and the apoptotic pathway.
Shendge AK; Basu T; Panja S; Chaudhuri D; Mandal N
Biomed Pharmacother; 2018 Oct; 106():454-465. PubMed ID: 29990833
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
15. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
[TBL] [Abstract][Full Text] [Related]
16. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A
Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.
Timoshnikov VA; Kobzeva TV; Polyakov NE; Kontoghiorghes GJ
Free Radic Biol Med; 2015 Jan; 78():118-22. PubMed ID: 25451643
[TBL] [Abstract][Full Text] [Related]
18. Metals, toxicity and oxidative stress.
Valko M; Morris H; Cronin MT
Curr Med Chem; 2005; 12(10):1161-208. PubMed ID: 15892631
[TBL] [Abstract][Full Text] [Related]
19. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox.
Adel RM; Lotfy RA; Darwish AS; Amer AS
J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Emara AM; El Kelany RS; Moustafa KA
Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
